Table 4 Post-hoc analysis: baseline characteristics and outcomes after propensity score matching
Controls (N = 70) | EXO-CD241 (N = 72) | p-value | |
|---|---|---|---|
Age (mean ± SD), years | 52.8 ± 12.0 | 52.3 ± 11.7 | p = 0.766 |
Male sex, n (%) | 40 (57.1) | 52 (72.2) | p = 0.06 |
BMI ≥ 30 kg/m2, n (%) | 29 (41.4) | 31 (43.1) | p = 0.844 |
Comorbidities, n (%) | |||
Current smoking | 5 (7.4) | 5 (6.9) | p = 0.925 |
Hypertension | 14 (20.0) | 16 (22.2) | p = 0.746 |
Dyslipidemia | 11 (15.7) | 14 (19.4) | p = 0.560 |
Diabetes | 7 (10.0) | 7 (9.7) | p = 0.956 |
CAD or HF | 3 (4.3) | 3 (4.2) | p = 0.972 |
COPD or asthma | 4 (5.7) | 7 (9.7) | p = 0.372 |
ESRD | 0 | 0 | – |
Autoimmune diseases | 1 (1.4) | 5 (6.9) | p = 0.102 |
NIAID-OS score, n (%) | p = 0.517 | ||
4 | 0 | 1 (1.4) | |
5 | 57 (81.4) | 55 (76.4) | |
6 | 13 (18.6) | 16 (22.2) | |
Concomitant medication, n (%) | |||
Antibiotics | 48 (68.6) | 49 (68.1) | p = 0.947 |
Remdesivir | 62 (88.6) | 60 (83.3) | p = 0.370 |
Dexamethasone | 70 (100) | 68 (94.4) | p = 0.045 |
Biologics2 | 21 (30.0) | 21 (29.2) | p = 0.913 |
Anticoagulants | p = 0.237 | ||
Prophylactic | 52 (74.3) | 46 (63.9) | |
Intermediate | 16 (22.9) | 18 (25.0) | |
Therapeutic | 2 (2.9) | 7 (9.7) | |
SpO2 ≥ 94% on room air, on Day 7, n (%) | 26 (37.1) | 40 (58.0) | p = 0.014 |
Decrease by 50% in either of the inflammatory markers3 from baseline to Day 7, n (%) | 38 (54.3) | 60 (83.3) | p < 0.001 |
Improvement in NIAID-OS from baseline to Day 7, median (IQR) | 0 (0–4) | 1 (0–2) | p = 0.863 |
Improvement in NIAID-OS of at least 1 point from baseline to Day 7, n (%) | 34 (48.6) | 44 (62.9) | p = 0.089 |
Death, n (%) | 0 | 1 (1.4) | p = 0.324 |
ICU admission, n (%) | 2 (2.9) | 2 (2.8) | p = 0.977 |
Admission to discharge in days, Median (IQR) | 8.5 (6–11) | 9 (7–14) | p = 0.544 |